<DOC>
	<DOCNO>NCT02072018</DOCNO>
	<brief_summary>Treatment Peyronie 's disease remain difficult . The purpose study test safety efficacy new compound treat disease .</brief_summary>
	<brief_title>Peyronie 's Disease Treatment Protocol</brief_title>
	<detailed_description />
	<mesh_term>Penile Induration</mesh_term>
	<criteria>1 . Have symptom ( ) Peyronie 's disease ( pain , curvature plaque ) 2 . Be judge good health , base upon result medical history , physical examination , laboratory profile 3 . Voluntarily sign date inform consent agreement approve Institutional Review Board/Independent Ethics Committee ( IRB/IEC ) . The subject must also sign authorization form allow disclosure protect health information ( PHI ) . The PHI authorization form inform consent form may integrate form may separate form depend institution 4 . Be able read , complete understand inform consent various rating instrument English 1 . Inability understand study goal risk 2 . Inability understand inform consent 3 . Inability achieve erection without PDE5 inhibitor use adequate penetration penile curvature limit factor 4 . Peyronie 's disease symptom great one year duration 5 . Chordee presence absence hypospadias Thrombosis dorsal penile artery vein Infiltration benign malignant mass result penile curvature Infiltration infectious agent , lymphogranuloma venereum Ventral curvature cause Presence active sexually transmitted disease Known active hepatitis B C Known immune deficiency disease positive human immunodeficiency virus ( HIV ) 6 . Has previously undergone surgery Peyronie 's disease 7 . Fails erection opinion investigator sufficient accurately measure subject 's penile deformity 8 . Has isolate hourglass deformity penis ( curvature cause plaque noncontiguous hourglass deformity may treat ) 9 . Has plaque cause curvature penis locate proximal base penis 10 . Has previously receive alternative medical therapy Peyronie 's disease administer intralesional route ( include , limited , steroid , verapamil , naturally occur low molecular weight protein , interferonÎ±2b ) within 3 month first dose study drug plan use medical therapy time study 11 . Has receive alternative medical therapy Peyronie 's disease administer oral ( include , limited , vitamin E [ &gt; 500 U ] , potassium aminobenzoate [ Potaba ] , tamoxifen , colchicine , pentoxifylline , overthecounter erectile dysfunction medication , steroidal antiinflammatory drug ) topical route ( include , limited , verapamil apply cream ) within 3 month first dose study drug plan use medical therapy time study 12 . Has extracorporeal shock wave therapy ( ESWT ) correction Peyronie 's disease within 6 month period screen plan ESWT time study 13 . Has use mechanical type device correction Peyronie 's disease within 2week period screen plan use device time study 14 . Has use mechanical device induce passive erection within 2week period screen plan use device time study 15 . Has significant erectile dysfunction fail respond oral treatment phosphodiesterase type 5 ( PDE5 ) inhibitors 16 . Has uncontrolled hypertension , determine investigator 17 . Has know recent history stroke , bleeding , significant medical condition , investigator 's opinion would make subject unsuitable enrollment study 18 . Is unwilling unable cooperate requirement study include completion schedule study visit 19 . Has receive investigational drug treatment within 30 day first dose study drug 20 . Has know systemic allergy H100 component 21 . Has receive collagenase treatment within 30 day first dose study drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Peyronie 's</keyword>
	<keyword>Peyronie 's disease</keyword>
	<keyword>Treatment</keyword>
	<keyword>Clinical Study</keyword>
</DOC>